Operator
I would now like to turn the call over to the CARA team. Please proceed.
Jack Hildick-Smith
Investor Relations
Good afternoon, this is Jack Hildick-Smith with Stern Investor Relations and welcome to Cara Therapeutics first quarter 2021 financial results and update conference call. The news release became available just after 4:00 PM today and can be found on our website at www.caratherapeutics.com. You may also listen to a live webcast and replay of today s call on the Investors section of the website.
Before we begin, let me remind you that statements made on today s call regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements, include statements concerning the expected timing of the data readouts from the company s planned and ongoing clinical trials, the potential results of ongoing clinical trials, timing of future regul
Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones
- Vadadustat New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA)
- Results of global Phase 3 programs for vadadustat published in New England Journal of Medicine
- Conference call today at 9:00 a.m. ET
News provided by
Share this article
®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today reported financial results for the first quarter ended March 31, 2021 and highlighted recent corporate milestones. The Company will host a conference call today, Monday, May 10, 2021, at 9:00 a.m. Eastern Time.
Search jobs 10-May-2021 Sesen Bio Reports First Quarter 2021 Financial Results and Commercial Launch Readiness Update in the US for Vicineum™
Strengthened balance sheet with $110M in cash and cash equivalents as of March 31, 2021
Company remains on track for potential approval in the US in August 2021 and in Europe in early 2022
Company to host conference call at 8am ET
CAMBRIDGE, Mass. (BUSINESS WIRE)
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the first quarter ended March 31, 2021. The Company’s Biologics License Application (BLA) for the Company’s lead program, Vicineum, is currently under Priority Review with the Food and Drug Administration (FDA) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with a target Prescription Drug User Fee Act (PDUFA) da
Operator
Ladies and gentlemen, welcome to the MorphoSys First Quarter 2021 Financial Results Conference Call. [Operator Instructions] And the conference is being recorded. [Operator Instructions] Now I d like to turn the conference over to Julia Neugebauer. Please go ahead.
Julia Neugebauer
Director of Corporate Communications & Investor Relations
Ladies and gentlemen, good afternoon and good morning. My name is Julia Neugebauer, Senior Director, Investor Relations at MorphoSys, and it s my pleasure to welcome you to our first quarter 2021 financial results conference call. Joining me on the call today are Jean-Paul Kress, Chief Executive Officer; Sung Lee, Chief Financial Officer; Roland Wandeler, Chief Operating Officer; and Malte Peters, Chief Research and Development Officer. Our press release was issued yesterday with our Q1 2021 financial results and business update.